allo-APZ2-OTS
- Generic Name
- allo-APZ2-OTS
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
- First Posted Date
- 2023-05-01
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- RHEACELL GmbH & Co. KG
- Target Recruit Count
- 74
- Registration Number
- NCT05838092
- Locations
- 🇺🇸
Masonic Cancer Center and Medical Center Minneapolis, Minneapolis, Minnesota, United States
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2023-02-24
- Lead Sponsor
- RHEACELL GmbH & Co. KG
- Target Recruit Count
- 74
- Registration Number
- NCT05464381
- Locations
- 🇦🇹
EB-Haus Austria; Salzburger Landeskliniken (SALK), Salzburg, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath